Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 5 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 13 patents granted in the last 365 days
Xencor Inc. currently has 9 pending office actions within the Biotechnology & Pharmaceuticals technology area. The prosecution is highly individualized, as there are 9 distinct examiners assigned to these 9 actions. This one-to-one ratio between actions and examiners means that every pending matter is being handled by a different official, requiring unique responses for each. The portfolio is spread across 6 distinct art units, providing technical variety despite the small number of 9 pending office actions.
BRADLEY DUFFY is the busiest examiner with 1 pending office action, a figure that is shared by all other examiners in this portfolio. This lack of concentration suggests that Xencor Inc. must address a wide range of examiner perspectives across its 6 distinct art units. Because each of the 9 pending office actions is in the hands of a different person, the company cannot rely on a single examiner's past behavior to predict outcomes across the portfolio. The 6 distinct art units further ensure that the 9 pending office actions are subject to diverse technical scrutiny within the Biotechnology & Pharmaceuticals field.
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (14%) |
| §112 only | 2 (29%) |
| Double-patenting + other | 1 (14%) |
| Multi-statute (no §101) | 3 (43%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NATARAJAN, MEERA | 1 | 62.5% | +18.0% |
| AEDER, SEAN E | 1 | 57.0% | +19.9% |
| OUSPENSKI, ILIA I | 1 | 77.5% | +20.4% |
| SHUPE, ELIZABETH A | 1 | 66.2% | +44.2% |
| HAM, JIEUN | 1 | 50.0% | +8.8% |
| YOUTCHOM PENDIE, EMMANUEL LED | 1 | 66.7% | +40.0% |
| CARTER, SANDRA DILLAHUNT | 1 | 56.2% | +29.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18300302 | ANTIBODIES THAT BIND PD-L1, PD-L2, AND/OR CD28 | HAM, JIEUN | 1d overdue |
| 18634868 | ANTI-CD28 X ANTI-ENPP3 ANTIBODIES | NATARAJAN, MEERA | — |
| 17815194 | IL-18-FC FUSION PROTEINS | CARTER, SANDRA DILLAHUNT | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18033165 | ANTI-CD20 ANTIBODIES AND THERAPEUTIC USES THEREOF | SHUPE, ELIZABETH A | 97d overdue |
| 18587839 | HETERODIMERIC ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENS | AEDER, SEAN E | 16d |
| 18053325 | BISPECIFIC ANTIBODIES THAT BIND TO B7H3 AND NKG2D | YOUTCHOM PENDIE, EMMANUEL LED | 29d |
| 18452395 | BISPECIFIC IMMUNOMODULATORY ANTIBODIES THAT BIND COSTIMULATORY AND CHECKPOINT RECEPTORS | OUSPENSKI, ILIA I | 46d |
| 18634868 | ANTI-CD28 X ANTI-ENPP3 ANTIBODIES | NATARAJAN, MEERA | — |
| 17815194 | IL-18-FC FUSION PROTEINS | CARTER, SANDRA DILLAHUNT | — |
| Art Unit | Apps |
|---|---|
| 1643 | 2 |
| 1642 | 1 |
| 1644 | 1 |
| 1647 | 1 |
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18634868 | ANTI-CD28 X ANTI-ENPP3 ANTIBODIES | NATARAJAN, MEERA | — | §103§112 | Non-Final OA | — | Pending | Apr 12, 2024 |
| 18587839 | HETERODIMERIC ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENS | AEDER, SEAN E | 1642 | §112Other | Final Rejection | 16d | Pending | Feb 26, 2024 |
| 18452395 | BISPECIFIC IMMUNOMODULATORY ANTIBODIES THAT BIND COSTIMULATORY AND CHECKPOINT RECEPTORS | OUSPENSKI, ILIA I | 1644 | §112Other | Non-Final OA | 46d | Pending | Aug 18, 2023 |
| 18033165 | ANTI-CD20 ANTIBODIES AND THERAPEUTIC USES THEREOF | SHUPE, ELIZABETH A | 1643 | §103DP | Final Rejection | 97d overdue | Pending | Apr 21, 2023 |
| 18300302 | ANTIBODIES THAT BIND PD-L1, PD-L2, AND/OR CD28 | HAM, JIEUN | 1643 | §102§112Other | Non-Final OA | 1d overdue | Pending | Apr 13, 2023 |
| 18053325 | BISPECIFIC ANTIBODIES THAT BIND TO B7H3 AND NKG2D | YOUTCHOM PENDIE, EMMANUEL LED | 1647 | §103 | Non-Final OA | 29d | Pending | Nov 07, 2022 |
| 17815194 | IL-18-FC FUSION PROTEINS | CARTER, SANDRA DILLAHUNT | 1674 | §102§103§112 | Non-Final OA | — | Pending | Jul 26, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial